Skip to main content

Advertisement

Table 2 Patient characteristics and clinical responses

From: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

No. Age Sex Target lesion Dose of peptide (mg) Number of injection Clinical response* Objective Response Response lesion Injection site reaction(Grade) CTL response PFS(day) OS (day) Pre-vaccination Post-vaccination
Pre-vaccination Post-vaccination**    WBC(/mm3) Lymphocyte (%) Lymphocyte (/mm3) WBC(/mm3) Lymphocyte (%) Lymphocyte (/mm3)
1 75 M Local LNs 1 4 PD    0 N.A. + 36 36 7300 7 511 5300 10.5 557
2 57 F Local 1 11 PD    1 ++ ++ 26 108 7400 13 962 7900 8 632
3 72 M Liver 1 3 -    0 N.T. N.T. 31 31 7800 11 858 16200 10.5 1701
4 60 M Lung, local LNs 1 19 SD Yes Lung metastasis 2 + - 223 283 5100 21 1071 5200 10.5 546
5 72 F Primary , liver 1 12 PD    1 + +++ 24 128 2400 25.5 612 4200 10.8 454
6 65 F Liver 1 4 PD    0 + + 26 40 4500 16.5 743 8000 4.1 328
7 61 F Local , liver 3 14 SD    2 + +++ 55 155 4000 25 1000 6400 18.3 1171
8 57 F Primary, liver 3 10 SD    2 ++ +++ 56 145 4500 33 1485 14100 16 2256
9 33 F Paraaortic LNs 3 29 SD Yes(CR) Liver metastasis 3 N.A. +++ >1219 >1219 2500 44.5 1113 3600 33 1188
10 76 M Liver 3 12 PD    2 - ++ 27 142 2300 29.5 679 5800 11.5 667
11 55 F Primary, lung 3 17 SD    1 + - 112 225 2600 9 234 2200 11.5 253
12 58 M Primary 3 5 PD    0 - - 32 32 4500 30 1350 2400 10.7 257
13 58 F Live, lung, LNs 3 10 SD    1 - ++ 57 97 7100 15.5 1101 9100 10.5 956
14 60 M Liver, LNs 3 17 SD Yes Liver metastasis, LNs 2 +++ +++ 169 220 2300 27 621 4100 19.5 800
15 80 F Liver, LNs, lung 3 5 PD    0 - + 24 44 8500 9.5 808 13300 4.8 638
16 58 M Primary, liver, lung 3 13 PD    1 - ++ 28 182 4800 27 1296 6400 19.3 1235
17 49 M Parimary 3 17 SD    2 + +++ 169 309 6200 26.5 1643 7900 17.5 1383
18 62 M Primary, liver, LNs 3 7 SD    1 - +++ 93 93 4200 28 1176 6600 18.6 1228
19 61 M Primarym, liver, lung, LNs 3 11 SD    2 - + 57 105 10200 20.5 2091 28700 9 2583
20 58 M LNs, lung 3 25 SD    2 + +++ 169 332 10100 34 3434 7600 19.5 1482
21 47 M Primary, liver 3 13 SD    1 - + 56 249 6000 27.5 1650 9600 8 768
22 71 F Liver, local LNs 3 7 SD Yes Liver metastasis 2 N.A. ++ 89 89 7000 11.5 805 5200 20 1040
23 50 M Local, LNs 3 6 SD    0 N.A. - 148 148 7900 20 1580 11200 19 2128
24 74 M Bone 3 21 SD Yes Bone metastasis 2 N.A. +++ 415 495 3800 16 608 5600 17.8 997
25 69 F Primary 3 2 -    0 N.T. N.T. 11 11 7600 21.5 1634 7400 20.5 1517
26 80 M Liver, lung 3 18 SD    1 + +++ 112 207 6600 24 1584 7500 21.5 1613
27 44 M Liver, lung, local LNs 3 24 SD Yes Lung and liver metastasis 1 + - 115 317 2900 23.5 682 4000 25.5 1020
28 61 F Peritoneal, local LNs 3 9 SD Yes Peritoneal metastasis 0 - - 69 69 9000 26.5 2385 11200 7.5 840
29 46 M Liver 3 10 SD    2 - +++ 52 388 4000 26 1040 5600 24.6 1378
30 64 F Liver 3 9 SD    2 - +++ 56 69 4800 26.5 1272 8900 7.1 632
31 68 F Liver 3 9 SD Yes Liver metastasis 2 + +++ 56 82 6800 33 2244 8300 19.5 1619
  1. *Clinical response was evaluated one month after vaccination. PD, Progressive disease; SD, Stable disease; CR, Complete response; OR, Objective response.
  2. **Best CTL response after vaccination. CTL responses were evaluated and classified based on the algorithm as described in Methods.
  3. N.T. (Not Tested); CTL response was not tested in the samples in which PD was observed within one course of the treatment.
  4. N.A. (Not Analyzed); CTL response was not analyzed because of the poor viability during the in vitro stimulation.